Mylan Launches Remdesivir Under the Brand Name Desrem for COVID-19 in India

 Mylan Launches Remdesivir Under the Brand Name Desrem for COVID-19 in India

Mylan Launches Generic Faslodex Injection for the Expansion of its Oncology Portfolio in the US

Shots:

  • Mylan launches Desrem (remdesivir) addressing the unmet needs amid COVID-19. The drug is approved for the treatment of suspected or laboratory-confirmed incidences of COVID-19 in adults and children hospitalized with severe symptoms
  • Mylan will manufacture Desrem in its state-of-the-art injectable facility in Bangalore, India, and other export markets where Mylan has received a license from Gilead for the commercialization of remdesivir
  • The company has released the first batch of its generic remdesivir and will continue to increase its supply across the country in the wake of the rising demand for the drug. Patients and HCPs can access information about the availability of Desrem in India through Mylan’s 24/7 national helpline number, +91.78299.80066

Click here to read full press release/ article | Ref: Mylan | Image: Ommcom News

Related News: Mylan’s Remdesivir Lyophilized Powder for Injection Receives the DCGI Accelerated Approval for Restricted Emergency Use in COVID-19 Patients in India

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post